Claim References

Reference Number

Associated Claim

1

In a prospective, double-blind, placebo-controlled clinical trial, iliadin® Metered Nose Spray (0,05 % m/v) demonstrated a statistically significant reducing of the duration of acute rhinitis by 2 days as compared to physiological saline solution and a mean onset of action after 25 seconds. Reinecke S, Tschaikin M. MMW - Fortschr Med. 2005;147(3):113-118.

2

Martindale. Thirty-eighth edition. The complete drug reference. Oxymetazoline Hydrochloride. Editor: Thomson Reuters.

3

Wegener and Grebe. JOURNAL PHARMAKOL. U THER.2012.21;3: 75-80.

4

IQVIA IMS TPM Data, Volumes, MAT, March 2022, IQVIA South Africa.

5

Impact Rx, Prescriber Analysis, South Africa, 1. March 2022

6

iliadin^®package leaflet.

7

Graf, P (2005). “Rhinitis medicamentosa: a review of causes and treatment.” Treatments in respiratory medicine 4(1):21–9

8

Bergner A, Tschaikin M. Treating rhinitis in babies and toddlers [German Paper]. Apotheker Zeitung 2005;145: 97-99

*

*iliadin^®Metered Nose Spray (0,05 % Oxymetazoline). Indicated for adults and children aged six years and older. Ask your doctor or pharmacist about the iliadin® product that is best suited for your family.